Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 201.2A Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
26 (19*) |
| Average PDX Generation Time (days +/- SEM) | 44 ± 2 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304; 30049486 |
| Markers | 201.2A Cx |
|---|---|
| AR | N |
| PSA | N |
| PSMA | N |
| NE | Y |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 201.2A Cx | AKT1 | -0.918 | 1.058 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | APC | -1.051 | 0.965 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | ARID4A | -0.996 | 1.003 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | CDKN1B | -1.066 | 0.955 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | CDKN2A | -1.004 | 0.997 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | CHD1 | -1.051 | 0.965 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | CHD7 | 0.559 | 2.946 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | CUL3 | -1.075 | 0.949 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | ERF | -0.919 | 1.058 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | MBD1 | -1.001 | 0.999 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | MYC | 0.960 | 3.891 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | PIK3CB | 0.506 | 2.840 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | PTEN | -14.129 | 1.117e-04 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | PTEN | -1.241 | 0.846 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | RB1 | -26.469 | 2.150e-08 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | SMAD2 | -1.001 | 0.999 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | SMARCAD1 | -1.010 | 0.993 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | SUFU | -1.241 | 0.846 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | TCERG1 | -0.999 | 1.000 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | TP53 | -0.845 | 1.113 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | USP28 | -1.003 | 0.998 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 201.2A Cx | ZNRF3 | -0.939 | 1.043 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 201.2A |
|---|---|
| Sample Site | Lung |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 201 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 201.2A |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 201.2A Cx | CTNNB1 | 474 | 1.0 | Missense variant | '3/15 | . | 29.9 | Pathogenic/likely pathogenic, other | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | AR | 255 | 1.0 | Missense variant | '8/8 | . | 25.3 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | TP53 | 258 | 1.0 | Missense variant | '8/11 | 1.22E-05 | 25.3 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | ZMYM3 | 184 | 0.98 | Frameshift variant | '8/25 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | MUTYH | 608 | 0.5 | Missense variant | '13/16 | 0.0007924 | 20.7 | Conflicting interpretations of pathogenicity | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | CACNA1H | 585 | 0.5 | Missense variant | '9/35 | 8.90E-05 | 5.716 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | MSH2 | 280 | 0.49 | Missense variant | '16/16 | 6.12E-05 | 27.7 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 201.2A Cx | ARID1A | 623 | 0.32 | Frameshift variant | '3/20 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table